Prevention and regression of atherosclerosis: Effects of HMG-CoA reductase inhibitors

Annals of Pharmacotherapy

Volumn 30, Issue 11, 1996, Pages 1304-1315

  Bjelajac, Aleksandra ^a,b,c   Goo, Alvin K Y ^a,d   Weart, C Wayne ^e,f  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KAISER PERMANENTE   (United States)

^e Department of Pharmacy Practice ^*  (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESTIPOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ANGIOCARDIOGRAPHY; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REMISSION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 0029926504     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001116     Document Type: Review

References (53)

1. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II), JAMA 1993;269:3015-23.
3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-74.
5. Manninen V, Elo O, Frick H, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
7. Dzau VJ. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994;128:1300-4.
8. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
9. Mitchinson MJ. The new face of atherosclerosis. Br J Clin Pharmacol 1994;48:149-51.
10. Brown BG, Lin JT, Kelsey S, Passamani ER, Levy RI, Dodge HT, et al. Progression of coronary atherosclerosis in patients with probable familial hypercholesterolemia: quantitative arteriographic assessment of patients in NHLBI Type II study. Arteriosclerosis 1989;9(suppl I):I81-90.
11. Webster MWI, Chesebro JH, Smith HC, Frye RL, Holmes DR, Reeder GS, et al. Myocardial infarction and coronary artery occlusion: a prospective 5-year angiographic study (abstract). J Am Coll Cardiol 1990;15 (suppl):218A.
12. Cohen M, Sherman W, Rentrop KP, Gorlin R. Determinants of collateral filling observed during sudden artery occlusion in human subjects. J Am Coll Cardiol 1989;13:297-303.
13. Fuster V, Frye RL, Kennedy MA, Connolly DC, Mankin HT. The role of collateral circulation in the various coronary syndromes. Circulation 1979;59:1137-44.
14. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
15. Noll G, Luscher TF. Influence of lipoproteins on endothelial function. Thromb Res 1994;74(suppl 1):S45-54.
16. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525-32.
17. Guretzki HJ, Gerbitz K-D, Oglemoller B, Schleicher E. Atherogenic levels of low-density lipoprotein alter the permeability and composition of the endothelial barrier. Atherosclerosis 1994;107:15-24.
18. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
19. Treasure CB, Klein JL, Weintraub WAS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
20. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991;87:87-90.
21. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
22. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. MARS Research Group. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969-76.
23. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am J Cardiol 1995;75:455-9.
24. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87.
25. Jukema JW, Bruschke AVG, van Boven Ad J, Reiber JHC, Bal ET, Zwinderman AH, et al. for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995;91:2528-40.
26. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
27. Pitt B, Mancini J, Ellis SG, Rossman HS, McGovern ME, for the PLAC I investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I). J Am Coll Cardiol 1994;(suppl):131A.
28. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
29. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
30. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi SJ, et al. for the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959-68.
31. Herd JA, West S, Ballantyne C, Farmer J, Gotto AM Jr. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol 1994;73(suppl):42D-9D.
32. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
33. Erratum. Am J Cardiol 1995;75:862.
34. Wallace RB, Hunninghake DB, Reiland S, Barrett-Connor E, MacKenthun A, Hoover J, et al. Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications: the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62(suppl IV):77-82.
35. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988;43:838-46.
36. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
37. McNamara JR, Compos H, Ordovas JM, Perterson J, Wilson PWF, Schaefer EJ. Effect of gender, age and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis 1987;7:483-90.
38. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993;34:1687-97.
39. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.
40. Krauss RM, Stampfer MJ, Blanche PJ, Holl LG, Ma J, Hennekens CH. A prospective study of LDL particle diameter and risk of myocardial infarction (abstract). Circulation 1994;90:I-460.
41. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-7.
42. McNamara JR, Jenner JL, Li ZL, Wilson PWF, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992;12:1284-90.
43. Fischer WR. Heterogeneity of plasma low density lipoprotein: manifestations of the physiologic phenomenon in man. Metabolism 1983;32:283-91.
44. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CD, Mayer EJ, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381-7.
45. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low-density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990;10:520-30.
46. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986;77:663-72.
47. Chait A, Brazg RL, Tribble DL. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-5.
48. Manninen V, Tenkanen L, Koskiene P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85: 37-45.
49. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
50. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM. Predominance of mid-density low density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study (abstract). Circulation 1994;90:I-460.
51. Krauss RM, Miller BD, Fair JM, Haskell WL, Alderman EL, SCRIP staff. Reduced progression of coronary artery disease with risk factor intervention in patients with LDL subclass pattern B (abstract). Circulation 1992;86(suppl):I-63.
52. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.
53. Superko HR, KOS Investigators. Effect of nicotinic acid on LDL subclass patterns (abstract). Circulation 1994;90(part 2):I-504.